Madrigal Pharmaceuticals, Inc. (United States)

Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for non-alcoholic steatohepatitis (NASH) and other metabolic liver diseases. The company created Rezdiffra (resmetirom), the first FDA-approved treatment for NASH, a serious liver condition associated with obesity and metabolic syndrome. Madrigal’s thyroid hormone receptor-beta agonist represents a breakthrough in fatty liver disease treatment.